TRANSLATIONAL RELEVANCE
Tumor-associated macrophages (TAMs) comprise a significant proportion of the cells in many tumors and may promote an immunosuppressive tumor microenvironment. TAM recruitment and survival is regulated by binding of colony-stimulating factor 1 (CSF1) or interleukin 34 (IL-34) to the CSF1 receptor (CSR1R). Inhibition of CSF1R significantly reduces the number of TAMs and inhibits tumor growth in several but not all preclinical models. AMG 820 is a fully human monoclonal antibody directed against human CSF1R that blocks ligand binding and receptor activation. We report the first-in-human clinical study of AMG 820 in patients with advanced solid tumors. AMG 820 was tolerated with manageable toxicities up to 20 mg/kg every 2 weeks. Pharmacodynamic response of reduced macrophages in skin biopsies was demonstrated and limited antitumor activity was observed. These data support continued investigation of AMG 820, with TAM depletion, providing an immunotherapeutic approach that is both distinct and potentially synergistic with immune checkpoint inhibitors. 
MATERIALS AND METHODS

Study Design
This was a phase I, first-in-human, open-label, sequential dose-escalation study. Primary endpoints included the incidence of DLTs and adverse events (AEs) and characterization of the AMG 820 pharmacokinetic profile. Secondary endpoints included tumor response as assessed per RECIST (24) and treatment-mediated changes in baseline levels of CSF1, IL-34, and tartrate-resistant acid phosphatase isoform 5b (TRAP5b). Exploratory endpoints included the pharmacokinetic-pharmacodynamic relationship for safety and/or efficacy endpoints.
Research. give all subsequent planned doses of AMG 820 (1.5, 3, 6, 10, and 20 mg/kg) once every 2 weeks (Q2W). A standard 3+3 dose-finding design was used. The original study protocol included a dose-expansion phase; however, a decision was made to terminate the study (not related to safety reasons) after the completion of the dose-escalation phase. The MTD was defined as the highest dose with 0 out of 3 patients or ≤1 out of 6 patients in each cohort without DLTs. Dose escalation continued until the maximum tolerated or planned dose was reached.
A DLT was defined as any grade ≥3 hematologic or nonhematologic toxicity (except alopecia) occurring between days 1 and 28, unless clearly attributable to causes other than AMG 820 treatment. Patients experiencing a DLT between days 1 and 28 discontinued AMG 820.
Patients withdrawn before day 28 for other than AMG 820-related reasons were replaced.
Patients who experienced grade ≥3 periorbital edema or conjunctival swelling had AMG 820 withheld until resolution to grade ≤2; those who required >4 weeks to recover to grade ≤2 were withdrawn from the study. Patients received AMG 820 until disease progression, intolerable AEs, investigator decision, or consent withdrawal. Samples for anti-AMG 820 antibody testing were collected predose at cycle 1 day 1, every 2 weeks, and at study termination and were analyzed using a validated bridging antibody immunoassay.
Pharmacodynamics and Biomarkers
Changes in macrophage populations after AMG 820 dosing were assessed in paired skin punch biopsies taken predose at screening, week 5, and week 13. Samples were processed for immunohistochemical analysis of CSF1R (CD115) and the macrophage markers CD68, CD163, and CD206 (Supplementary Methods). To assess the biomarkers CSF1, IL-34, and TRAP5b, blood samples were collected and analyzed by standard sandwich ELISA methods. Blood samples for CSF1 and IL-34 were collected concurrently with pharmacokinetic samples; for TRAP5b, a marker of osteoclast activity, the samples were collected predose at weeks 1, 3, 5, 9, every 8 weeks thereafter, and end of study.
Statistical Analysis
The sample size in this study was determined empirically, and there was no formal hypothesis testing. Categorical and continuous data were summarized with frequencies and percentages or descriptive statistics, respectively. All patients who received at least one dose of AMG 820
were included in the safety analyses; the efficacy population included all patients in the safety population with a baseline assessment and at least one postbaseline tumor assessment. 
RESULTS
Patients
Dose-Limiting Toxicity and Maximum Tolerated Dose
One DLT, grade 3 irreversible bilateral hearing loss 12 days after the first dose of AMG 820, occurred in a female patient with anal cancer who received 20 mg/kg AMG 820 Q2W ( Table 2) .
This patient had previously received ≥5 cycles of potentially ototoxic cisplatin, the last of which was administered 1 month before the first dose of AMG 820. The patient did not report hearing loss at study entry nor was there a baseline audiology examination; thus, considering the temporal relationship between bilateral hearing loss and AMG 820 administration, this toxicity was attributed to AMG 820. The MTD was not determined; the preplanned 20-mg/kg dose was the highest dose tested, with both the 10-and 20-mg/kg doses showing sustained pharmacodynamic responses, as described in a later section.
Safety and Tolerability
The median number of doses given for each dose group is shown in Table 2 . Patients received between 1 and 21 doses of AMG 820. Treatment-related AEs occurred in 19 (76%) of the 25 patients (Table 3) ; the most common (≥5% of patients overall) were periorbital edema (44%; n=11), increased aspartate aminotransferase (AST; 28%, n=7), fatigue (24%, n=6), nausea (16%, n=4), increased blood alkaline phosphatase (12%, n=3), and blurred vision (12%, n=3).
Seven patients (28%) had grade 3 treatment-related AEs that were not considered to be DLTs: four (16%) had increased AST, two (8%) had hypertension, and one (4%) had periorbital edema after three doses of AMG 820 10 mg/kg. Treatment-related increases in AST above baseline were apparent at the time of the second dose of AMG 820 (cycle 1 day 15), and resolved after AMG 820 was withheld or discontinued. Two of the four patients with grade 3 elevation of AST attributed to AMG 820 had concurrent progression of liver metastases. There were no grade 4, serious, or fatal treatment-related AEs. Three patients in the 10-mg/kg cohort and three patients in the 20-mg/kg cohort had their AMG 820 dose reduced or withheld for treatmentemergent AEs.
Of the 11 patients with periorbital edema, 10 were grade ≤2 (grade 1, n=7; grade 2, n=3) and were mostly managed without intervention. One patient with grade 3 periorbital edema had AMG 820 withheld until resolution to grade 2. One patient with grade 2 periorbital edema also had AMG 820 dosing withheld. Supportive measures, including steroids and diuretics, were instituted at the treating physician's discretion (n=4).
Research. 
Pharmacokinetics
The pharmacokinetic analysis included all 25 patients, with mean concentration-time profiles shown for all doses in Fig. 1A . Intravenous infusion at 0.5 mg/kg was characterized by apparent time and concentration dependency in AMG 820 elimination, possibly due to targetmediated drug disposition. With increases in dose level from 1.5 to 6 mg/kg, estimates of median t 1/2 and mean V ss were increased, and mean CL was decreased after single intravenous administration (Supplementary Table S1 ). Although these trends suggest that AMG 820 was Table S1 ). At the highest doses (10 and 20 mg/kg Q2W), AMG 820 trough concentrations were at or above the target serum concentration of anti-mouse CSFR1 antibody found to be efficacious in a mouse NCI-H1650 tumor xenograft model (mean ± standard deviation, 140 ± 56.5 µg/mL) to reduce tumor volume and deplete TAMs ( Supplementary   Fig. S1 ).
All 25 patients tested negative for anti-AMG 820 binding antibodies.
Pharmacodynamics
Serum CSF1 concentrations increased with increasing AMG 820 dose and concentration (Fig. 1B) . CSF1 levels in the lowest dose cohort (0.5 mg/kg) were increased initially but returned to baseline before the next dosing cycle, reflecting concurrent decreases in circulating Fig. S2 ). At higher doses, elevated CSF1 levels were maintained over a 2-week dosing cycle with apparent maximal levels of approximately 1500 ng/mL being reached at AMG 820 doses ≥6 mg/kg. AMG 820 demonstrated concentration-and dose-dependent modulation of circulating CSF1 concentrations, consistent with CSF1R saturation by AMG 820. Serum levels of the putative biomarkers IL-34 and TRAP5b showed no significant treatment-related changes (Supplementary Fig. S3 ).
Eight paired predose and postdose skin biopsies from eight patients were available for analysis of macrophage density. One patient in the 0.5-mg/kg QW group showed little change from baseline in macrophage density at week 13. In the seven patients treated with 10 mg/kg (n=3) and 20 mg/kg (n=4), AMG 820 dosing was associated with significantly reduced numbers of CD68+, CD163+, and CD206+ skin macrophages as well as CSF1R levels at week 5 compared with baseline ( Fig. 2A and B; Supplementary Fig. S4 ). The reduction in macrophage density between 10-and 20-mg/kg doses was not significantly different ( Fig. 2A) .
Antitumor Activity
Fifteen patients were evaluable for tumor response. By central review, eight patients (32%) had a best response of stable disease (SD). One patient with non-small-cell lung cancer, previously treated with erlotinib, who received 0.5 mg/kg AMG 820 QW, showed a 25% reduction in sum of longest tumor diameters, and remained on study for 12 weeks. Two patients, one with paraganglioma and liver metastases (10-mg/kg AMG 820 dose), and another with pancreatic neuroendocrine tumor who progressed on everolimus (20-mg/kg AMG 820 dose), experienced SD ≥16 weeks. Seven patients (28%) had progressive disease as best response. Ten patients (40%) ended the study before the first postbaseline scan (prior to week 9 dosing) and were therefore not assessable. Best tumor responses by primary tumor type and dose group are shown (Fig. 3) .
DISCUSSION
In this first-in-human phase I study, AMG 820 was tolerated with manageable toxicities at doses up to 20 mg/kg Q2W. One DLT occurred at the maximum administered dose of 20 mg/kg; without baseline audiometry as reference, the toxicity of irreversible bilateral hearing loss was attributed to AMG 820. The MTD was not determined; doses ≥10 mg/kg resulted in trough serum concentrations higher than that found to be effective in preclinical models, and serum levels of the pharmacodynamic marker CSF1 rapidly increased and levels plateaued at doses ≥6 mg/kg Q2W. Safety and pharmacodynamic data support further development of AMG 820 at 20 mg/kg.
The most common treatment-related AEs with AMG 820 were periorbital edema (44%) and increased AST (28%). In the 11 patients with periorbital edema, all received AMG 820 doses ≥1.5 mg/kg Q2W. All except one were grade ≤2 and resolved following drug discontinuation; most were managed without intervention or with diuretics and/or corticosteroids. In preclinical AMG 820 toxicology studies in cynomolgus monkeys, reversible periorbital or conjunctival swelling of generally minimal to moderate severity was observed in all animals. The mechanism leading to periorbital edema is unclear, although rearrangements in the extracellular matrix may be involved based on preclinical toxicology studies in cynomolgus monkeys (Amgen Inc., data on file). Treatment-related increases in AST resolved after withholding treatment. Half of the patients with treatment-related grade 3 AST increases had concurrent progression of liver lesions, which confounds attribution. Isolated elevation of AST may reflect depletion of Kupffer cells, which function to maintain serum enzyme homeostasis, rather than hepatotoxicity. (22, 27) Furthermore, histologic findings in cynomolgus monkeys suggested that moderate increases in AST were not related to hepatotoxicity (Amgen Inc., data on file). Nevertheless, these results indicate that close monitoring of hepatotoxicity is warranted for future trials. Both of these AEs appear to be a class effect as they have been reported in clinical studies of the CSF1R- Research.
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